Table 1 Demographics and baseline characteristics of patients with and without enthesitis at baseline
Characteristic | With enthesitis at baseline | Without enthesitis at baseline | ||||
|---|---|---|---|---|---|---|
Secukinumab | Placebo (N = 163) | Secukinumab | Placebo (N = 72) | |||
300 mg (N = 144) | 150 mg (N = 159) | 300 mg (N = 95) | 150 mg (N = 79) | |||
Age (years), mean (SD) | 48.3 (12.5) | 48.0 (11.8) | 48.9 (13.3) | 46.5 (13.7) | 48.7 (12.8) | 50.4 (11.9) |
Female, % | 55 | 53 | 69 | 44 | 48 | 33 |
Weight (kg), mean (SD) | 88.1 (21.0) | 90.8 (19.4) | 82.9 (18.9) | 83.8 (15.1) | 84.1 (17.8) | 85.3 (16.4) |
Caucasian, % | 95 | 93 | 97 | 96 | 92 | 96 |
TNFi-naïve, % | 68 | 63 | 64 | 67 | 72 | 72 |
Time since first diagnosis of PsA (years), mean (SD) | 7.7 (8.7) | 7.4 (8.8) | 6.8 (7.0) | 8.2 (8.4) | 6.7 (7.6) | 7.1 (8.0) |
Number of enthesitis sites, mean (SD) | 3.0 (1.7) | 3.2 (1.7) | 3.0 (1.6) | 0 | 0 | 0 |
Tender joint total score (78 joints), mean (SD)* | 23.5 (15.6) | 27.0 (19.8) | 26.3 (18.4) | 14.6 (9.6) | 16.9 (13.6) | 14.1 (11.2) |
Swollen joint total score (76 joints), mean (SD)* | 10.3 (6.9) | 12.2 (10.1) | 12.1 (10.3) | 9.3 (7.4) | 10.0 (8.1) | 8.6 (7.1) |
DAS28-CRP, mean (SD) | 4.8 (1.0) | 4.9 (1.1) | 4.9 (1.1) | 4.3 (1.0) | 4.4 (1.1) | 4.3 (0.9) |
HAQ-DI, mean (SD) | 1.3 (0.7) | 1.2 (0.6) | 1.3 (0.6) | 1.0 (0.6) | 1.2 (0.6) | 1.1 (0.7) |
Patient global assessment, mean (SD) | N = 142, 62.6 (18.7) | N = 156, 61.6 (21.6) | N = 161, 62.2 (20.1) | N = 95, 56.6 (21.5) | N = 79, 59.1 (19.9) | N = 72, 53.1 (19.9) |
Physician global assessment, mean (SD) | N = 143, 54.4 (18.3) | N = 158, 57.0 (16.4) | N = 163, 57.1 (15.7) | N = 94, 51.0 (16.8) | N = 79, 53.6 (17.0) | N = 72, 49.9 (19.4) |